The low-dose recombinant tissue plasminogen activator alteplase did not reduce 30-day major adverse cardiac events (MACE) in patients undergoing percutaneous coronary intervention (PCI) for ST-Segment elevation myocardial infarction (STEMI) and large thrombus burden in a randomized trial, closing the chapter on the potential treatment option.